Stocks Health care CBIO
NASDAQ · Health careCrescent Biopharma, Inc. (CBIO)
It posted a net loss of $96M. In fiscal 2025 capital spending exceeded operating cash flow by $72.5M. At June 30, 2026 it held $171.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 30, 2026.
Key facts about Crescent Biopharma, Inc.
- Net worth
- Crescent Biopharma, Inc. has a market value (market cap) of $507M at the latest share price, and shareholders' equity of $163.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $10.8M (+108,340.0% year on year), with a net loss of $153.9M.
- Cash flow
- In fiscal 2025 operations used $71.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on July 30, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Crescent Biopharma, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Crescent Biopharma, Inc. does
Crescent Biopharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CBIO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $10.8M | -$153.9M | n/a | -$72.5M |
| 2024 | n/a | -$37.9M | -$0.59 | -$31.1M |
| 2023 | $10K | -$36.9M | -$0.58 | -$34.9M |
| 2022 | $75K | -$46.7M | -$0.89 | -$46.5M |
| 2021 | $1.2M | -$63.4M | -$1.23 | -$57.5M |
| 2020 | $10.2M | -$51M | -$1.12 | -$39.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CBIO ranks in Health care
Latest SEC filings
What Crescent Biopharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 27, 2026Passive stake (5% or more) SCHEDULE 13G
- October 15, 2026Other event 8-K
- September 18, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- July 30, 2026Form POS AM filing POS AM
- July 30, 2026
- July 30, 2026
- July 20, 2026Activist stake changed SCHEDULE 13D/A
- July 15, 2026Other event 8-K
- July 14, 2026
Insider trades
What the people running Crescent Biopharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $285.5K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 18, 2026 | McNeill JonathanPresident and COO | Soldpre-planned (10b5-1) | 3,839 | $64.1K |
| September 18, 2026 | Brumm Joshua TChief Executive Officer, Director | Soldpre-planned (10b5-1) | 7,837 | $131K |
| September 16, 2026 | McNeill JonathanPresident and COO | Soldpre-planned (10b5-1) | 731 | $13.1K |
| September 16, 2026 | Brumm Joshua TChief Executive Officer, Director | Soldpre-planned (10b5-1) | 1,610 | $28.8K |
| September 16, 2026 | Bispham Barbara HarlinSee Remarks | Soldpre-planned (10b5-1) | 620 | $11.1K |
| September 16, 2026 | Scalzo Richard WilliamChief Financial Officer | Soldpre-planned (10b5-1) | 568 | $10.2K |
| September 16, 2026 | Im Ellie EunkyungChief Medical Officer | Soldpre-planned (10b5-1) | 623 | $11.2K |
| September 16, 2026 | Pinkas JanChief Scientific Officer | Soldpre-planned (10b5-1) | 658 | $11.8K |
Who owns CBIO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Peter Harwin13D, may seek influence with 3 related filers | 16.52% | July 20, 2026 |
| Fmr LLC13G, passive with 1 related filers | 15% | February 5, 2026 |
| 1Globe Capital LLC13G, passive with 1 related filers | 10.3% | October 14, 2025 |
| Bvf Partners L P13G, passive with 9 related filers | 9.99% | August 14, 2025 |
| Venrock Healthcare Capital Partners III, L.P.13G, passive with 6 related filers | 9.5% | February 17, 2026 |
| ForGrowth III PA B.V.13G, passive with 2 related filers | 6.1% | December 11, 2025 |
| Balyasny Asset Management L.P.13G, passive with 4 related filers | 6.03% | August 14, 2026 |
| BlackRock, Inc.13G, passive | 5.6% | October 27, 2026 |
| Vestal Point Capital, LP13G, passive with 1 related filers | 5.4% | February 17, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 82 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 4,133,514 | 0 |
| Bvf Inc | 2,748,763 | 0 |
| Fairmount Funds Management LLC | 2,747,866 | 0 |
| Venrock Adviser, LLC | 2,133,576 | 0 |
| Logos Global Management LP | 1,900,000 | +1,417,500 |
| Fcpm III Services B.V. | 1,677,852 | 0 |
| Balyasny Asset Management L.P. | 1,662,917 | +152,884 |
| Vestal Point Capital, LP | 1,630,000 | +130,000 |
| Opaleye Management Inc. | 1,319,351 | +6,736 |
| BlackRock, Inc. | 1,271,762 | +1,156,037 |
| Tang Capital Management LLC | 1,160,000 | 0 |
| Vanguard Capital Management LLC | 767,755 | -33,640 |
| Boxer Capital Management, LLC | 453,686 | 0 |
| Millennium Management LLC | 403,859 | +80,306 |
| Geode Capital Management, LLC | 384,576 | +280,355 |
| Jennison Associates LLC | 378,507 | +225,533 |
| Rtw Investments, LP | 372,856 | 0 |
| NEXTBio Capital Management LP | 372,856 | 0 |
| Remedium Capital Partners, LLC | 361,250 | 0 |
| State Street Corp | 315,587 | +276,520 |
Insiders
9 insiders reported holding 4,164,961 shares in total, about $56.9M at the last price.
| Holder | Shares |
|---|---|
| Fairmount Funds Management LLCDirector, 10% owner | 3,601,3163,601,316 held indirectly |
| Brumm Joshua TChief Executive Officer, Director | 271,765 |
| McNeill JonathanPresident and COO | 134,588 |
| Doughty Christopher GrantChief Business Officer | 62,194 |
| Pinkas JanChief Scientific Officer | 21,581 |
| Im Ellie EunkyungChief Medical Officer | 21,446 |
| Scalzo Richard WilliamChief Financial Officer | 19,730 |
| Bispham Barbara HarlinSee Remarks | 18,710 |
| Lynch RyanSee Remarks | 13,631 |
Questions about CBIO
What does Crescent Biopharma, Inc. do?
Crescent Biopharma, Inc. is a company in the Health care sector, listed on NASDAQ as CBIO. Its shares trade on NASDAQ under the ticker CBIO.
What is Crescent Biopharma, Inc.'s net worth?
Crescent Biopharma, Inc. has a market value (market cap) of $507M at the latest share price, and shareholders' equity of $163.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Crescent Biopharma, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $96M.
When did Crescent Biopharma, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 30, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from October 27, 2026.
When is Crescent Biopharma, Inc.'s next earnings report?
Crescent Biopharma, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare CBIO with
Follow CBIO
Get an email when Crescent Biopharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Crescent Biopharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.